Company / FCF Margin
Apellis Pharmaceuticals, Inc. FCF Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
4.5%
FY2025
5-year range
-847.7% / 4.5%
FY2021-FY2025
Trend
+139.6%
vs FY2024
Sector context
#55 of 134
Health Care
What the data says
At 4.5%, Apellis Pharmaceuticals, Inc.'s fcf margin ranks #55 of 134 in the Health Care sector. FCF Margin has increased for 4 consecutive years, from -847.7% in FY2021 to 4.5% in FY2025.
Based on SEC 10-K filings.
4.5% in FY2025 with a 5-year CAGR of +70.7%.
Improved from -150.2% to 4.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +687.7pp
- 5-Year Change
- +70.7pp
- 10-Year Change
- -
Sector benchmark
#55 of 134 in Health CareTop 41% of 134This company 4.5% Sector average -637.8%
▼
+100.7% above sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s fcf margin has grown for 4 consecutive years.
- In FY2025, fcf margin increased 139.6% year-over-year.
- Currently 642.3pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 4.5% | +139.6% |
| FY2024 | -11.3% | +92.5% |
| FY2023 | -150.2% | +78.0% |
| FY2022 | -683.2% | +19.4% |
| FY2021 | -847.7% | -1180.6% |
| FY2020 | -66.2% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026